Allarity Therapeutics, Inc. (ALLR) company profile
Close on Nov 17, 2026Market cap $13.38MP/E –Yield –
About Allarity Therapeutics
Pharmaceutical Preparations, SIC 2834
Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company developing targeted cancer therapeutics. The company focuses on its lead therapeutic candidate, stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) and tankyrases being evaluated in clinical trials for advanced ovarian cancer and relapsed small cell lung cancer. In conjunction with drug development, the business utilizes its proprietary Drug Response Predictor (DRP) companion diagnostic platform to identify patients most likely to benefit from specific treatments. It also provides DRP analysis and gene expression laboratory services to external biotechnology clients.
The company operates its clinical research across trial sites located in the United States and Europe. It also maintains external out-licensing and development partnerships, including collaboration with Chosa Oncology. Allarity Therapeutics maintains its principal executive offices in Tarpon Springs, Florida.
Summary of the business section of Allarity Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Allarity Therapeutics, Inc.
- Founded
- 2004
- Headquarters
- Boston, MA
- Address
- 24 School St., 2nd Floor 02108
- Phone
- (401) 426-4664
- Website
- allarity.com
- Employees
- 8, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Wolf & Company P.C., Boston, Massachusetts
Stock & identifiers
- Ticker
- ALLR
- Exchange
- Nasdaq
- IPO date
- Dec 21, 2021
- Shares outstanding
- 16M, Aug 14, 2026
- Public float
- $14.73M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-30 reverse, Sep 11, 2024; 1-for-20 reverse, Apr 9, 2024; 1-for-40 reverse, Jun 29, 2023; 1-for-35 reverse, Mar 27, 2023
- SEC CIK
- 1860657
- CUSIP
- 016744500
- ISIN
- US0167445008
- FIGI
- BBG012NXCZP8
- Share class FIGI
- BBG012NXCZQ7
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeremy R. Graff | See Remarks | 80,095 |
| Thomas Jensen | CEO | 596,734 |
| Jeffrey S. Ervin | CFO | 150,000 |
| Alexander Epshinsky | CFO | 85,051 |
| Jesper Hoeiland | Director | 25,000 |
| Gerald W. McLaughlin | Director | 70,000 |
| Laura Benjamin | Director | – |
| Joseph Walter Vazzano | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Thomas H. Jensen Chief Executive Officer | $647.38K | $355.50K | $400.70K | $55.37K | $1.46M | +84% |
| Jeffrey S. Ervin Chief Financial Officer | $119.62K | $35.98K | – | $2.93K | $158.53K | – |
| Jeremy R. Graff President and Chief Development Officer | $494.00K | $222.30K | $145.89K | $46.63K | $908.82K | +75% |
| Steen Knudsen Chief Scientific Officer | $168.35K | $68.45K | – | – | $236.80K | +20% |
| Alexander Epshinsky Former Chief Financial Officer | $176.80K | – | – | $206.75K | $383.55K | +10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight employees; seven of whom were full-time and one part-time.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?